Related Experiment Video
Updated: Jun 14, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data
Johanna Vikkula1, Kari Remes2, Outi Laatikainen3
1Medaffcon Oy, Espoo, Finland.
Acta Haematologica
|June 12, 2026
Summary
New therapies improved outcomes for younger multiple myeloma (MM) patients at first relapse, but older MM patients saw little change in treatment or survival. Improved care is needed for elderly MM patients.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Characterizing MM patients at first relapse is crucial for understanding treatment efficacy.
- Outcomes for relapsed MM can vary significantly based on patient demographics and treatment advancements.
Purpose of the Study:
- To characterize multiple myeloma patients at their first relapse.
- To examine and compare treatment outcomes in relapsed MM patients.
- To identify disparities in care and outcomes between different age groups.
Main Methods:
- Retrospective registry-based study of relapsed MM patients (2013-2022) in Finland.
- Patient data collected from multiple health registries.
- Stratification by age (≤70 vs >70), index year, and time to first relapse.
Main Results:
- 286 relapsed MM patients met inclusion criteria.
- Median overall survival from relapse was 32.4 months for younger (<70) vs 20.0 months for older (>70) patients.
- Younger patients received newer therapies (CD38-based, pomalidomide) post-2018, unlike older patients.
Conclusions:
- Significant advancements in MM treatment are benefiting younger patients.
- Older MM patients at first relapse have experienced limited changes in therapy and poorer outcomes.
- There is an unmet need to enhance treatment strategies and care for elderly MM patients.
